Cullinan Therapeutics, Inc. (CGEM)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
15.06 USD
+0.32
(2.171%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 15.01 -0.05 (-0.049%) ⇩ (April 17, 2026, 6:27 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:20 a.m. EDT
Despite a 'Strong Buy' analyst consensus and a bullish earnings backdrop, the price structure is trapped. The market is pricing in a significant downside event around the $12 level in the coming months, creating a harsh floor while the short-term technicals struggle to find buying pressure above the recent highs. Fundamentally, this is a cash-rich but cash-burn-heavy biotech play (high short ratio, negative earnings) with no dividend safety net, making it suitable only for high-risk capital chasing clinical milestones rather than value accumulation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.114493 |
| AutoARIMA | 0.121454 |
| AutoETS | 0.121456 |
| AutoTheta | 0.121634 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 4.55 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.410 |
| Excess Kurtosis | -0.85 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.656 |
| Market Cap | 911,523,520 |
| Forward P/E | -5.24 |
| Beta | -0.11 |
| Previous Name | Cullinan Management, Inc. |
| Website | https://cullinantherapeutics.com |
As of April 19, 2026, 1:20 a.m. EDT: Speculative positioning is mixed but weighted slightly bearish for the near term. In the May 15 expiry (approx. 1 month), there is a notable 'New Flow' of 36 calls at the $15 ATM strike, suggesting some immediate bullish chatter at current prices. However, this is contrasted by a massive wall of out-of-the-money put Open Interest (OI) at the $12 strike for the July and December expirations, which acts as a significant resistance floor for speculation, while total call OI for those further expirations remains thin. ATM IV is elevated (~1.4) relative to underlying strikes, indicating a compensation for risk, but put volume is actively chasing the downside protection provided by the $15 strikes in long-term expirations.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.85925925 |
| Address1 | One Main Street |
| Address2 | Suite 1350 |
| All Time High | 59.85 |
| All Time Low | 5.68 |
| Ask | 15.09 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 731,180 |
| Average Daily Volume3 Month | 809,304 |
| Average Volume | 809,304 |
| Average Volume10Days | 731,180 |
| Beta | -0.111 |
| Bid | 14.99 |
| Bid Size | 1 |
| Board Risk | 4 |
| Book Value | 6.785 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 15.06 |
| Current Ratio | 10.248 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 15.2 |
| Day Low | 14.77 |
| Debt To Equity | 0.656 |
| Display Name | Cullinan Therapeutics |
| Earnings Timestamp | 1,773,145,800 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -241,336,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.222 |
| Enterprise Value | 536,310,496 |
| Eps Current Year | -3.05806 |
| Eps Forward | -2.87593 |
| Eps Trailing Twelve Months | -3.36 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.9496 |
| Fifty Day Average Change | 1.1104002 |
| Fifty Day Average Change Percent | 0.07960086 |
| Fifty Two Week Change Percent | 85.92593 |
| Fifty Two Week High | 16.74 |
| Fifty Two Week High Change | -1.6799994 |
| Fifty Two Week High Change Percent | -0.10035838 |
| Fifty Two Week Low | 5.68 |
| Fifty Two Week Low Change | 9.380001 |
| Fifty Two Week Low Change Percent | 1.6514087 |
| Fifty Two Week Range | 5.68 - 16.74 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,610,116,200,000 |
| Float Shares | 43,207,787 |
| Forward Eps | -2.87593 |
| Forward P E | -5.236567 |
| Free Cashflow | -100,281,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 109 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00418 |
| Held Percent Institutions | 1.0552601 |
| Implied Shares Outstanding | 60,526,128 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-01-08 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Cullinan Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 911,523,520 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_539392639 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -219,879,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 910,312,965 |
| Number Of Analyst Opinions | 11 |
| Open | 15.0 |
| Operating Cashflow | -175,750,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 410 4650 |
| Post Market Change | -0.04940033 |
| Post Market Change Percent | -0.32802343 |
| Post Market Price | 15.0106 |
| Post Market Time | 1,776,464,853 |
| Prev Name | Cullinan Management, Inc. |
| Previous Close | 14.74 |
| Price Eps Current Year | -4.924691 |
| Price Hint | 2 |
| Price To Book | 2.219602 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.088 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.08333 |
| Region | US |
| Regular Market Change | 0.320001 |
| Regular Market Change Percent | 2.17097 |
| Regular Market Day High | 15.2 |
| Regular Market Day Low | 14.77 |
| Regular Market Day Range | 14.77 - 15.2 |
| Regular Market Open | 15.0 |
| Regular Market Previous Close | 14.74 |
| Regular Market Price | 15.06 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 835,049 |
| Return On Assets | -0.28225002 |
| Return On Equity | -0.44017 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 60,526,128 |
| Shares Percent Shares Out | 0.1387 |
| Shares Short | 8,394,357 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 8,080,892 |
| Short Name | Cullinan Therapeutics, Inc. |
| Short Percent Of Float | 0.1598 |
| Short Ratio | 9.79 |
| Source Interval | 15 |
| State | MA |
| Symbol | CGEM |
| Target High Price | 38.0 |
| Target Low Price | 24.0 |
| Target Mean Price | 31.35455 |
| Target Median Price | 30.0 |
| Total Cash | 377,896,000 |
| Total Cash Per Share | 6.244 |
| Total Debt | 2,683,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.36 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.99245 |
| Two Hundred Day Average Change | 5.0675507 |
| Two Hundred Day Average Change Percent | 0.50713795 |
| Type Disp | Equity |
| Volume | 835,049 |
| Website | https://cullinantherapeutics.com |
| Zip | 2,142 |